EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor
| Autor: | Oguz Guven, Serkan Yılmazer, Sadık Görür, İsmet Melek, Soner Akcin, Esra Okuyucu, Taskin Duman |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
Time Factors Phosphodiesterase Inhibitors Electroencephalography Tadalafil Cohort Studies Erectile Dysfunction medicine Humans medicine.diagnostic_test Eeg abnormalities General Medicine Middle Aged Phosphodiesterase 5 Inhibitors medicine.disease Erectile dysfunction Neurology Anesthesia cGMP-specific phosphodiesterase type 5 Neurology (clinical) Psychology Cohort study medicine.drug Carbolines |
| Zdroj: | Neurological research. 31(3) |
| ISSN: | 0161-6412 |
| Popis: | Objective: Tadalafil is a selective phosphodiesterase type 5 (PDE-5) inhibitor approved for the treatment of erectile dysfunction. Less is known about the electroencephalography (EEG) effects of PDE-5 inhibitors, and the present study, therefore, examined the risk of EEG abnormalities associated with tadalafil. Method: EEG recordings from 35 erectile dysfunction patients taking tadalafil (20 mg) were graded for severity of EEG abnormalities (at admission, 2 and 48 hours after tadalafil administration). Results: At admission, there were no EEG abnormalities. At second EEG, abnormalities occurred in 12 (34.3%) of the 35 patients. Eight (22.9%) patients had mild and four (11.4%) patients had moderate EEG abnormalities. At third EEG, one (2.9%) patient had mild and one (2.9%) patient had moderate EEG abnormalities. Conclusion: PDE-5 inhibitors may produce EEG abnormalities. Although the exact role of PDE in altering susceptibility to seizure remains unclear, epileptic seizures may occur during treatm... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|